BioMarin settles with Par Pharmaceutical on patent for tablets and powder

BioMarin Pharmaceutical has resolved patent litigation in the United States regarding its Kuvan 100mg oral tablets and powder for oral solution in 100mg packets, it had with Par Pharmaceutical.

According to the settlement, BioMarin will grant Par a non-exclusive license to its patents related to Kuvan to allow Par to market a generic version of sapropterin dihydrochloride 100mg tablets and powder for oral solution in 100mg and 500 mg sachets in the U.S. for the indications approved for Kuvan beginning October 1, 2020 or earlier under certain circumstances. said the company.

BioMarin said that it holds patents in Europe related to Kuvan that are valid until at least 2024.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.